Floatz logo

vx-970

HRD Cancer

National Cancer Institute (NCI)Phase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the HRD Cancer cohort.

Asset / SponsorPhaseRating
Dat-2645
Danatlas Pharmaceuticals Co., Ltd
Phase 1CC

Same molecule, other indications

vx-970 is also rated in:

small cell lung carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →
small cell carcinomaDormant
BB
Indicative ·
64 / 100
View asset →
fallopian tube carcinomaDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →